FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy
Thyroid® · 2024
DOI: 10.1089/thy.2024.0216 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Thyroid®, 2024. Verfasst von Mark F Sabbagh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background
Diagnostic classification of thyroid malignancy is primarily accomplished through examination of histomorphological features and may be substantiated and clarified by molecular data. Individual molecular drivers show relatively robust and specific associations with histological subtypes of thyroid malignancy, including BRAF sequence variants and kinase gene fusions in papillary thyroid carcinoma, predominantly RAS variants in follicular-patterned neoplasia, and additional “late” mutations affecting TERT promoter, TP53 , and the PI3K/AKT/PTEN pathway in high-grade malignancies. Given the oncogenic role of FGFR , particularly FGFR1-3 , the goal of this study was to explore the role of FGFR in thyroid carcinoma biology.
Methods
We completed a multicenter retrospective observational study for thyroid carcinomas with pathogenic alterations in the FGFR gene family. We performed this study by querying the molecular data accumulated for thyroid carcinomas from each center.
Results
Overall, 5030 sequenced thyroid malignancies were reviewed, yielding 17 tumors with FGFR alterations, including 11 where FGFR was the primary molecular driver and 6 where FGFR was a secondary pathogenic alteration, with a subset for which there was available clinical follow-up data. Of the 11 carcinomas with an FGFR driver, 9 were gene fusions involving FGFR2:VCL (4 tumors), TG::FGFR1 (3 tumors), FGFR2::CIT , and FGFR2::SHTN1 , and the remaining 2 were driven by FGFR1 amplification. In the 6 tumors where a canonical driver of thyroid neoplasia was present (5 cases) or no clear primary driver was detected (1 case), sequencing detected secondary FGFR2 p.W290C, p.Y375C, and p.N549K, as well as FGFR1 p.N546K in the respective tyrosine kinase domains, some at subclonal variant allele frequencies.
Conclusions
This study presents the first description of a collection of thyroid carcinomas grouped by primary driver alterations in FGFR , as well as a cohort of thyroid tumors with secondary alterations that potentially lead to tumor progression or resistance to targeted therapy. Given the availability of small molecular inhibitors targeting oncogenic FGFR , this study emphasizes the significant implications for patients from identification of FGFR alterations as they are currently under-recognized in the literature and, most importantly, have potential novel treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Foundation Medicine, Inc., Cambridge, Massachusetts, USA.
- Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
- Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Departments of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA, USA.
- BostonGene Corporation, Waltham, Massachusetts, USA.
ORCID-Profile: Mark F Sabbagh, Lori J Wirth, Bayan A Alzumaili, William C Faquin, Peter M Sadow, Adam S Fisch
Zitieren
APA
Sabbagh, M. F., Janovitz, T., Dias-Santagata, D., Siegmund, S., Nardi, V., Wirth, L. J., Randolph, G. W., Lennerz, J. K., Decker, B., Nose, V., Alzumaili, B. A., Faquin, W. C., Barletta, J. A., Le, L. P., Iafrate, A. J., Sadow, P. M., & Fisch, A. S. (2024). FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy. Thyroid®. https://doi.org/10.1089/thy.2024.0216
Vancouver
Sabbagh MF, Janovitz T, Dias-Santagata D, Siegmund S, Nardi V, Wirth LJ, et al. FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy. Thyroid®. 2024. doi:10.1089/thy.2024.0216
BibTeX
@article{Sabbagh2024,
author = {Sabbagh, Mark F and Janovitz, Tyler and Dias-Santagata, Dora and Siegmund, Stephanie and Nardi, Valentina and Wirth, Lori J and Randolph, Gregory W and Lennerz, Jochen K and Decker, Brennan and Nose, Vania and Alzumaili, Bayan A and Faquin, William C and Barletta, Justine A and Le, Long P and Iafrate, A John and Sadow, Peter M and Fisch, Adam S},
title = {FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy},
journal = {Thyroid®},
year = {2024},
doi = {10.1089/thy.2024.0216}
}
EUVIMED